title: Determining the non-inferiority margin for patient reported outcomes.
abstract: One of the cornerstones of any non-inferiority trial is the choice of the non-inferiority margin delta. This threshold of clinical relevance is very difficult to determine, and in practice, delta is often "negotiated" between the sponsor of the trial and the regulatory agencies. However, for patient reported, or more precisely patient observed outcomes, the patients' minimal clinically important difference (MCID) can be determined empirically by relating the treatment effect, for example, a change on a 100-mm visual analogue scale, to the patient's satisfaction with the change. This MCID can then be used to define delta. We used an anchor-based approach with non-parametric discriminant analysis and ROC analysis and a distribution-based approach with Norman's half standard deviation rule to determine delta in three examples endometriosis-related pelvic pain measured on a 100-mm visual analogue scale, facial acne measured by lesion counts, and hot flush counts. For each of these examples, all three methods yielded quite similar results. In two of the cases, the empirically derived MCIDs were smaller or similar of deltas used before in non-inferiority trials, and in the third case, the empirically derived MCID was used to derive a responder definition that was accepted by the FDA. In conclusion, for patient-observed endpoints, the delta can be derived empirically. In our view, this is a better approach than that of asking the clinician for a "nice round number" for delta, such as 10, 50%, π, e, or i.
authors.affiliation: Bayer Pharma AG-Global Clinical Statistics. christoph.gerlinger@bayer.com
authors.forename: Christoph
authors.initials: C
authors.lastname: Gerlinger
authors.forename: Thomas
authors.initials: T
authors.lastname: Schmelter
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy; D017486:Acneiform Eruptions / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000379:methods*; D016002:Discriminant Analysis; D018450:Disease Progression; D004335:Drug and Narcotic Control; D064420:Drug-Related Side Effects and Adverse Reactions; D004715:Endometriosis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D019584:Hot Flashes / Q000150:complications / Q000188:drug therapy; D006801:Humans; D038622:Internationality; D008593:Menopause / Q000187:drug effects; D015233:Models, Statistical; D017060:Patient Satisfaction; D017699:Pelvic Pain / Q000150:complications*; D004364:Pharmaceutical Preparations / Q000378:metabolism; D012372:ROC Curve; D012107:Research Design; D057566:Self Report / Q000592:standards*; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014666:Vasomotor System / Q000187:drug effects
chemical_list: D004364:Pharmaceutical Preparations